spire1 Antibody

What is SPIRE1 and why is it important in cellular research?

SPIRE1 (Spire homolog 1) is an actin nucleation factor that remains associated with the slow-growing pointed end of new filaments and plays critical roles in cytoskeletal dynamics . It belongs to the family of Wiskott-Aldrich homology region-2 (WH2) proteins . Its importance in research stems from:

• Its fundamental role in actin polymerization and filament assembly

• Its involvement in intracellular vesicle transport along actin fibers

• Its participation in DNA damage response by promoting nuclear actin filament assembly

• Its regulatory functions in cellular architecture maintenance

SPIRE1 has been implicated in multiple cellular processes including spermatogenesis, mitochondrial dynamics, and exocytosis, making it a valuable target for studying cytoskeletal regulation .

For optimal SPIRE1 immunofluorescence staining, follow this validated protocol:

• Culture cells on collagen-coated coverslips (12 mm diameter) until they reach approximately 80% confluency

• Fix cells with 4% PFA in PBS for 10 minutes at room temperature

• Permeabilize using 0.1% Triton X-100 in PBS for 4 minutes

• Block unspecific binding with 3% BSA in PBS for at least 30 minutes

• Incubate with primary SPIRE1 antibody (typically 1:200 dilution) in 3% BSA in PBS overnight at 4°C

• Apply secondary antibodies at 1:200 dilution for 40 minutes at room temperature

• Wash extensively and mount in appropriate mounting medium

For mitochondrial SPIRE1 (mitoSPIRE1) detection, additional considerations for permeabilization method are crucial as demonstrated in comparative studies using Triton-X 100 vs. Digitonin permeabilization .

What controls should I include when using SPIRE1 antibodies?

When using SPIRE1 antibodies, include the following controls to ensure valid results:

• Positive tissue controls: Human lung cancer tissue has been validated for SPIRE1 expression

• Negative controls: Omit primary antibody but include all other reagents

• RNAi validation: Include samples treated with SPIRE1-specific siRNA to demonstrate antibody specificity

• Cross-reactivity controls: If studying specific SPIRE1 isoforms (e.g., mitoSPIRE1), include controls for other isoforms

• Peptide competition: Pre-incubation of antibody with immunizing peptide should abolish specific staining

For enrichment of low-abundance endogenous SPIRE1, GST-FMN2-eFSI pulldown has been validated as an effective approach before immunoblot detection .

How can I differentiate between SPIRE1 isoforms using antibodies?

Distinguishing between SPIRE1 isoforms requires strategic antibody selection and experimental design:

• Antibody epitope mapping: Use antibodies targeting differential regions - for example, antibodies recognizing all SPIRE1 isoforms (anti-SPIRE1-CT) versus those specific to exon 13-containing isoforms

• Subcellular fractionation: mitoSPIRE1 localizes to mitochondria while other isoforms have different distributions

• Differential permeabilization technique:

  • Triton-X 100 permeabilization allows antibody penetration into mitochondria

  • Digitonin permeabilization restricts antibody access to the cytoplasm

  • This differential permeabilization can be used to distinguish mitochondrial versus cytoplasmic SPIRE1

For RT-PCR verification of isoform expression, primer design targeting specific exons (e.g., exon 13 for mitoSPIRE1) has been validated in knockout models .

What strategies can overcome detection challenges with low-abundance SPIRE1?

SPIRE1 is typically expressed at low levels, requiring specific strategies for reliable detection:

• Protein enrichment approaches:

  • Use GST-FMN2-eFSI pulldown to concentrate endogenous SPIRE1 before immunoblotting

  • Implement immunoprecipitation using GFP-Trap beads for tagged SPIRE1 variants

  • Scale up starting material (e.g., using three 10 cm plates instead of one while maintaining 25 μl of beads)

• Signal amplification methods:

  • Employ tyramide signal amplification for immunohistochemistry

  • Use high-sensitivity detection reagents for Western blot

  • Optimize antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0 have been validated)

• Validated detection parameters:

  • Molecular weight confirmation: SPIRE1 appears at 50-60 kDa and 95 kDa bands in immunoblots

  • Storage of antibody at -20°C with 0.02% sodium azide and 50% glycerol pH 7.3 maintains stability

How can SPIRE1 antibodies be applied to study actin dynamics in specialized cellular structures?

SPIRE1 antibodies have been instrumental in studying actin dynamics in specialized structures:

• Ectoplasmic specialization (ES) in spermatogenesis:

  • SPIRE1 localizes to both apical ES (at the convex side of spermatid heads) and basal ES/BTB

  • Co-localization studies with F-actin, Arp3, Eps8, β1-integrin, nectin-2/3, N-cadherin, and γ-catenin provide insights into ES dynamics

  • SPIRE1 knockdown by RNAi disrupts F-actin and microtubule organization across the seminiferous epithelium

• Weibel-Palade bodies (WPB) in endothelial cells:

  • SPIRE1 associates with mature WPB and concentrates in ring-like structures with F-actin at fusion sites during Ca²⁺-evoked exocytosis

  • SPIRE1 depletion reduces actin ring formation and decreases von Willebrand factor externalization after histamine stimulation

• Mitochondrial motility regulation:

  • Antibodies against mitoSPIRE1 have been used to track its role in coordinating actin/myosin functions in mitochondrial dynamics

How can I implement SPIRE1 knockdown experiments to study its function?

SPIRE1 knockdown studies have revealed important insights into its cellular functions. Two validated approaches include:

In vitro cell culture knockdown:

• Culture cells until establishing functional barriers/junctions (e.g., day 3 for Sertoli cells)

• Transfect with SPIRE1-specific siRNA duplexes (50-150 nM depending on application)

• Use RNAiMAX as transfection reagent for 24 hours

• Remove transfection reagents with three washes and replace with fresh medium

• Continue culture for appropriate timepoints (e.g., day 5 for RNA analysis, day 6 for protein/functional analyses)

• For immunofluorescence studies, co-transfect with 1 nM siGLO red transfection indicator to track successful transfection

In vivo knockdown:

• Prepare SPIRE1-specific siRNA duplexes

• Use Polyplus in vivo-jetPEI as transfection medium (demonstrated high transfection efficiency)

• Implement multiple transfections (e.g., on days 1, 3, 5)

• Validate knockdown efficiency by qPCR (typically ~70% knockdown is achievable)

• Confirm specificity by measuring expression of related proteins (e.g., SPIRE2 should remain unaffected)

This approach has successfully demonstrated SPIRE1's role in maintaining epithelial integrity and cytoskeletal organization in testicular tissue .

How can I address non-specific binding when using SPIRE1 antibodies?

Non-specific binding is a common challenge when working with SPIRE1 antibodies. Implement these validated solutions:

• Blocking optimization:

  • Extend blocking time with 3% BSA in PBS beyond the standard 30 minutes

  • Test alternative blocking agents (e.g., normal serum from the same species as secondary antibody)

  • Use commercial blocking solutions specifically designed for sensitive applications

• Antibody dilution optimization:

  • Perform titration experiments to determine optimal dilution range (e.g., 1:50-1:500 for IHC)

  • For each new batch of antibody or cell/tissue type, revalidate optimal dilution

• Washing protocols:

  • Implement extended and more frequent washing steps

  • Use washing buffers containing 0.05-0.1% Tween-20 to reduce background

• Validation of specificity:

  • Confirm knockdown effects using siRNA

  • Include peptide competition controls

  • Test multiple antibodies targeting different epitopes of SPIRE1

What are the critical parameters for successful detection of SPIRE1 in tissue sections?

For optimal SPIRE1 detection in tissue sections, consider these critical parameters:

• Antigen retrieval methods:

  • TE buffer pH 9.0 is recommended as primary method

  • Citrate buffer pH 6.0 can be used as an alternative

• Tissue fixation considerations:

  • Overfixation can mask SPIRE1 epitopes

  • Standardize fixation times for consistent results

  • Consider testing different fixatives if standard protocols yield poor results

• Antibody incubation conditions:

  • Overnight incubation at 4°C typically yields best results

  • Humidity chamber use prevents sample drying

• Signal development optimization:

  • Adjust development times based on signal intensity

  • Consider signal amplification for tissues with low SPIRE1 expression

• Common tissue-specific challenges:

  • Human lung cancer tissue serves as a reliable positive control

  • Testicular tissue requires special attention to fixation parameters to preserve ES structures

How can I validate antibody specificity when studying SPIRE1 in novel cell types or tissues?

When investigating SPIRE1 in previously unstudied systems, antibody validation is crucial:

• Genetic approaches:

  • Use CRISPR/Cas9 or siRNA to create SPIRE1-deficient samples as negative controls

  • Employ overexpression systems with tagged SPIRE1 as positive controls

• Isoform specificity verification:

  • Use RT-PCR to confirm which SPIRE1 isoforms are expressed in your system

  • Target specific exons (e.g., exon 13 for mitoSPIRE1)

• Cross-platform validation:

  • Confirm antibody reactivity across multiple techniques (WB, IF, IHC)

  • Expected molecular weights: 50-60 kDa and 95 kDa bands

• Immunoprecipitation validation:

  • Perform IP-MS to confirm antibody captures SPIRE1 and its known binding partners

  • ChromoTek Agarose GFP-Trap® beads protocol has been validated for SPIRE1 studies

• Comparative antibody testing:

  • Test multiple antibodies targeting different SPIRE1 epitopes

  • Compare reactivity patterns between monoclonal and polyclonal antibodies

How does SPIRE1 colocalization with other proteins inform its function?

SPIRE1 colocalization studies have revealed important insights about its functional interactions:

• Actin cytoskeleton components:

  • SPIRE1 partially colocalizes with actin microfilaments in Sertoli cell cytosol

  • At the apical ES, SPIRE1 prominently localizes to the convex side of spermatid heads with F-actin

  • SPIRE1 shows minor but consistent colocalization with Arp3 (branched actin nucleation protein) and Eps8 (actin barbed end capping and bundling protein) at the concave side of spermatid heads

• Cell junction proteins:

  • SPIRE1 colocalizes with apical ES proteins β1-integrin, nectin-2, and nectin-3 at the convex side of spermatid heads

  • At the basal ES/BTB, SPIRE1 colocalizes with N-cadherin and γ-catenin

  • Knockdown disrupts distribution of junction proteins (CAR, ZO-1, N-cadherin, β-catenin)

• Mitochondrial markers:

  • GFP-mitoSPIRE1 colocalizes with the mitochondrial intermembrane space marker cytochrome C only when permeabilization allows antibody penetration into mitochondria

These colocalization patterns suggest SPIRE1 functions in coordinating cytoskeletal dynamics at specialized cell junctions and organelle interfaces.

What quantitative approaches can be used to analyze SPIRE1 antibody staining patterns?

Several quantitative methods have been validated for SPIRE1 staining analysis:

• Fluorescence intensity measurement:

  • Measure relative fluorescence intensity to quantify protein levels

  • Knockdown efficiency can be assessed (~75% reduction based on fluorescence intensity analysis is achievable)

• Colocalization analysis:

  • Calculate Pearson's correlation coefficient to determine degree of colocalization with other proteins

  • Manders' overlap coefficient to determine proportion of SPIRE1 associated with specific structures

• Distribution pattern quantification:

  • Line scan analysis across cell-cell interfaces to assess junction localization

  • Internalization index to measure redistribution from cell cortex to cytoplasm following experimental manipulations

• Functional correlation metrics:

  • Barrier integrity measurements (e.g., TJ-permeability) correlated with SPIRE1 distribution

  • Actin organization metrics (bundling vs. branching) correlated with SPIRE1 levels

• Live-cell dynamics:

  • Track SPIRE1-positive structures during cellular processes like exocytosis

  • Quantify ring formation frequency at fusion sites

How can SPIRE1 antibodies be used to investigate DNA damage response mechanisms?

SPIRE1 plays a crucial role in DNA damage response through nuclear actin filament assembly. Antibody-based approaches to study this function include:

• Nuclear translocation studies:

  • Track SPIRE1 localization before and after DNA damage induction

  • Quantify nuclear vs. cytoplasmic SPIRE1 levels using subcellular fractionation and immunoblotting

  • Employ super-resolution microscopy to visualize nuclear SPIRE1 organization

• Interaction partner identification:

  • Use co-immunoprecipitation with SPIRE1 antibodies to capture DNA damage-specific protein complexes

  • Confirm SPIRE1-FMN2 interactions during DNA damage response

  • Analyze post-translational modifications of SPIRE1 following damage

• Chromatin association analysis:

  • Perform chromatin immunoprecipitation (ChIP) to identify damage-specific chromatin regions associated with SPIRE1

  • Investigate SPIRE1's role in facilitating movement of chromatin and repair factors after DNA damage

• Functional rescue experiments:

  • Deplete endogenous SPIRE1 using siRNA and reintroduce mutant variants to identify domains critical for DNA damage response

  • Combine with repair kinetics assays to correlate SPIRE1 function with repair efficiency

This approach reveals how SPIRE1 coordinates actin dynamics to support genome integrity maintenance.

What are the technical considerations when using SPIRE1 antibodies in co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) with SPIRE1 antibodies requires special considerations due to the protein's low abundance and complex interactions:

• Starting material optimization:

  • Scale up starting material (e.g., three 10 cm dishes instead of one per condition)

  • Maintain appropriate bead volume (e.g., 25 μl of GFP-Trap beads)

• Lysis buffer selection:

  • Use buffers that preserve SPIRE1 interactions with actin and binding partners

  • Consider crosslinking approaches for transient interactions

• Enrichment strategies:

  • For endogenous SPIRE1, GST-FMN2-eFSI pulldown has been validated to concentrate SPIRE1 before detection

  • For tagged variants, ChromoTek Agarose GFP-Trap® beads provide efficient capture

• Detection strategies:

  • Use highly sensitive chemiluminescence substrates

  • Consider gel gradient optimization to resolve SPIRE1 isoforms (observed at 50-60 kDa and 95 kDa)

• Verification approaches:

  • Perform reverse Co-IP with antibodies against suspected interaction partners

  • Include appropriate controls (IgG control, lysate input, non-specific proteins)

  • Validate specificity with SPIRE1 knockdown samples

These strategies enable successful investigation of SPIRE1's protein interaction network despite its challenging detection profile.

How can SPIRE1 antibodies be used to investigate its role in exocytosis and secretory processes?

Recent research has revealed SPIRE1's critical role in secretory processes, particularly in endothelial cells:

• Weibel-Palade body (WPB) exocytosis studies:

  • SPIRE1 antibodies reveal its association with mature WPB

  • Upon Ca²⁺-evoked exocytosis, SPIRE1 concentrates with F-actin in ring-like structures at fusion sites

  • Quantification of these rings correlates with von Willebrand factor (VWF) externalization

• Live-cell imaging approaches:

  • Combine SPIRE1 antibody staining with histamine stimulation (500 μM)

  • Perform imaging at 37°C in medium containing 20 mM HEPES using 8-chamber μ-slides

  • Use Plan-Apochromat 63×/1.4 oil immersion objective for optimal resolution

• Functional correlation analysis:

  • SPIRE1 depletion reduces actin ring formation at fusion sites

  • This correlates with decreased VWF externalization after stimulation

  • Provides mechanistic insight into how cytoskeletal organization supports secretion

This research direction reveals SPIRE1's broader role in coordinating cytoskeletal dynamics during regulated secretory processes beyond its established functions in actin nucleation.

What are the considerations when studying SPIRE1 in mitochondrial dynamics?

The mitochondrial isoform of SPIRE1 (mitoSPIRE1) requires specific experimental considerations:

• Isoform-specific detection:

  • Use antibodies targeting the exon 13 region for mitoSPIRE1 specificity

  • Employ differential permeabilization techniques (Triton-X 100 vs. Digitonin) to distinguish mitochondrial from cytoplasmic localization

• Mitochondrial motility analysis:

  • Track mitochondria in living fibroblast cells to assess mitoSPIRE1's impact on movement

  • Correlate mitochondrial transport with actin/myosin organization

  • Compare wild-type and mitoSPIRE1 knockout models

• Multi-protein complex analysis:

  • Investigate interactions between mitoSPIRE1 and myosin motor proteins

  • Study actin organization at mitochondrial surfaces

  • Employ SPIRE1 knockout models with specific deletion of exon 13 sequences

• Verification strategies:

  • Combine antibody staining with GFP-tagged mitoSPIRE1 expression

  • Use RT-PCR to confirm exon 13-containing transcripts

  • Western blot analysis with antibodies recognizing all SPIRE1 isoforms (anti-SPIRE1-CT) vs. isoform-specific antibodies

This approach enables investigation of SPIRE1's specialized role in coordinating cytoskeletal functions at mitochondrial membranes.

How can researchers resolve contradictory findings related to SPIRE1 function across different cell types?

Resolving contradictions in SPIRE1 research requires systematic comparative approaches:

• Isoform expression profiling:

  • Comprehensively characterize SPIRE1 isoform expression across cell types

  • Use RT-PCR targeting specific exons (e.g., exon 13 for mitoSPIRE1)

  • Western blot analysis with pan-SPIRE1 antibodies and isoform-specific antibodies

• Interaction partner differences:

  • Compare SPIRE1 binding partners across cell types using co-immunoprecipitation

  • Identify cell-type specific regulators that may modify SPIRE1 function

  • Analyze post-translational modifications that may differ between contexts

• Functional domain analysis:

  • Generate domain-specific mutants to determine which regions mediate cell-type specific functions

  • Perform rescue experiments in SPIRE1-depleted cells using various truncated constructs

  • Use chimeric proteins to identify domains responsible for specialized functions

• Context-dependent regulation:

  • Investigate upstream regulators of SPIRE1 that may differ between cell types

  • Examine signaling pathways that converge on SPIRE1 in different cellular contexts

  • Study temporal dynamics of SPIRE1 activity in response to various stimuli

This systematic approach can reconcile seemingly contradictory findings by revealing how cellular context shapes SPIRE1 function.